Investors of Applied Therapeutics Urged to Act in Class Action Filing by February 18, 2025
In a recent announcement from the esteemed law firm Robbins Geller Rudman & Dowd LLP, investors who experienced significant financial losses with Applied Therapeutics, Inc. (NASDAQ: APLT) are being invited to play a crucial role in a proposed class action lawsuit. This opportunity is limited as the deadline for interested parties to apply as lead plaintiffs is fast approaching on February 18, 2025. Investors who purchased or acquired securities of Applied Therapeutics between January 3, 2024, and December 2, 2024, are particularly urged to participate.
The class action, filed in the Southern District of New York under the name Alexandru v. Applied Therapeutics, Inc., centers around allegations of fraudulent behavior by the executives of the company in relation to the Securities Exchange Act of 1934. Specifically, the suit claims the defendants misled investors by failing to adhere to established trial protocols and good clinical practices, potentially compromising the integrity of submitted trial data that the FDA would evaluate for the approval of a new drug application.
On January 3, 2024, Applied Therapeutics announced the submission of their New Drug Application (NDA) for a treatment called govorestat aimed at Classic Galactosemia. However, as the class action lawsuit indicates, the company’s announcements were fraught with misleading information regarding the approval process and the underlying trials. In November 2024, the FDA issued a Complete Response Letter concerning the NDA, highlighting deficiencies in the clinical application, leading to a staggering drop in the company's stock price—over 80% within a few trading sessions.
Adding further gravity to the situation, a follow-up disclosure on December 2 indicated that the FDA had warned Applied Therapeutics about issues related to the electronic data capture during the clinical trial, resulting in another sharp decline in stock value by 26%. Therefore, there is a critical need for affected investors to come together in seeking justice against the company and its executives.
Leading the class action provides impacted investors a voice, as well as an opportunity to resolve grievances collectively. With the ability to select representation, potential lead plaintiffs can choose a legal team that best aligns with their expectations in navigating this lawsuit. Notably, participating as a lead plaintiff does not affect an investor's eligibility for any financial recovery that may arise from the lawsuit, ensuring that their involvement is truly a collective endeavor aimed at transparency and accountability.
Robbins Geller Rudman & Dowd LLP stands at the forefront of litigating securities class actions and has an impressive track record of recovering billions for their clients in similar situations. As one of the largest dedicated plaintiffs' firms globally, their ongoing commitment to ensuring investor rights are protected remains paramount. If you believe you are eligible to join this class action or know any affected investors, further information can be accessed through Robbins Geller’s detailed online resources or by reaching out directly via phone or email.
In conclusion, for those who are worried about the severe implications of their investments in Applied Therapeutics, taking prompt action to get involved in this proposed class action lawsuit might be your best recourse. The reality is that the clock is ticking, and collective power may prove essential in this venture towards justice for all affected parties.
The class action, filed in the Southern District of New York under the name Alexandru v. Applied Therapeutics, Inc., centers around allegations of fraudulent behavior by the executives of the company in relation to the Securities Exchange Act of 1934. Specifically, the suit claims the defendants misled investors by failing to adhere to established trial protocols and good clinical practices, potentially compromising the integrity of submitted trial data that the FDA would evaluate for the approval of a new drug application.
On January 3, 2024, Applied Therapeutics announced the submission of their New Drug Application (NDA) for a treatment called govorestat aimed at Classic Galactosemia. However, as the class action lawsuit indicates, the company’s announcements were fraught with misleading information regarding the approval process and the underlying trials. In November 2024, the FDA issued a Complete Response Letter concerning the NDA, highlighting deficiencies in the clinical application, leading to a staggering drop in the company's stock price—over 80% within a few trading sessions.
Adding further gravity to the situation, a follow-up disclosure on December 2 indicated that the FDA had warned Applied Therapeutics about issues related to the electronic data capture during the clinical trial, resulting in another sharp decline in stock value by 26%. Therefore, there is a critical need for affected investors to come together in seeking justice against the company and its executives.
Leading the class action provides impacted investors a voice, as well as an opportunity to resolve grievances collectively. With the ability to select representation, potential lead plaintiffs can choose a legal team that best aligns with their expectations in navigating this lawsuit. Notably, participating as a lead plaintiff does not affect an investor's eligibility for any financial recovery that may arise from the lawsuit, ensuring that their involvement is truly a collective endeavor aimed at transparency and accountability.
Robbins Geller Rudman & Dowd LLP stands at the forefront of litigating securities class actions and has an impressive track record of recovering billions for their clients in similar situations. As one of the largest dedicated plaintiffs' firms globally, their ongoing commitment to ensuring investor rights are protected remains paramount. If you believe you are eligible to join this class action or know any affected investors, further information can be accessed through Robbins Geller’s detailed online resources or by reaching out directly via phone or email.
In conclusion, for those who are worried about the severe implications of their investments in Applied Therapeutics, taking prompt action to get involved in this proposed class action lawsuit might be your best recourse. The reality is that the clock is ticking, and collective power may prove essential in this venture towards justice for all affected parties.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.